Dabrafenib plus trametinib in patients with previously treated BRAFV600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial by Planchard, David, MD, Besse, Benjamin, MD, Groen, Harry J M, Prof, Souquet, Pierre-Jean, MD, Quoix, Elisabeth, Prof, Baik, Christina S, MD, Barlesi, Fabrice, Prof, Kim, Tae Min, MD, Mazieres, Julien, Prof, Novello, Silvia, MD, Rigas, James R, MD, Upalawanna, Allison, PharmD, D'Amelio, Anthony M, PhD, Zhang, Pingkuan, MD, Mookerjee, Bijoyesh, MD, Johnson, Bruce E, Prof

Get full text

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage,... by Konecny, Gottfried E, Dr, Finkler, Neil, Prof, Garcia, Agustin A, MD, Lorusso, Domenica, MD, Lee, Paula S, MD, Rocconi, Rodney P, MD, Fong, Peter C, MBBS, Squires, Matt, PhD, Mishra, Kaushal, PhD, Upalawanna, Allison, PharmD, Wang, Yongyu, MD, Kristeleit, Rebecca, MD

Get full text

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial by Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D'Amelio, Jr, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E

Get full text

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer by Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D’Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E

Get full text

PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC: Topic: Medical Oncology by Rybkin, Igor I., Smit, Egbert, Kopp, Hans-Georg, Kim, Dong-Wan, Spira, Alexander, Berruti, Alfredo, Lee, Dae Ho, Reguart, Noemí, Akimov, Mikhail, Schumacher, Karl, Upalawanna, Allison, Squires, Matthew, Tan, Daniel S.-W.

Get full text

PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC by Rybkin, Igor I., Smit, Egbert, Kopp, Hans-Georg, Kim, Dong-Wan, Spira, Alexander, Berruti, Alfredo, Lee, Dae Ho, Reguart, Noemí, Akimov, Mikhail, Schumacher, Karl, Upalawanna, Allison, Squires, Matthew, Tan, Daniel S.-W.

Get full text